-
A Phase 2a Multicenter Randomized Double-Blind Placebo- Controlled Study of the Safety and Efficacy of TB006 in Participants with Parkinson s Disease
The purpose of this study is to see if the study drug improves motor function in Parkinson's disease (PD) patients. -
PNOC029: Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
This study is designed for patients who have craniopharyngioma (a rare brain tumor). The usual treatment for craniopharyngioma involves surgery and radiation, which helps reduce ...
-
A multi-center randomized (1:1) controlled phase 2 trial of STIMULAN VG with debridement and a course of systemic antibiotics vs standard of care (SoC) for the treatment of osteomyelitis associated with stage IV pressure ulcers.
This study is being performed to find out if the use of a new investigational product (meaning not approved by the Food and Drug Administration ... -
AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to
The purpose of the study is to study the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell ...
-
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
This is a Phase 2, open-label, pan tumor trial which enrolls participants from ongoing companysponsored studies (Bristol-Myers Squibb Company [BMS] Parent Studies) that evaluated nivolumab ... -
A Multi-Center Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CK-4021586 in Adults with Symptomatic Heart Failure with Preserved Ejection Fraction
The purpose of this study is to learn about the safety and how well participants tolerate various doses of CK-4021586 when taken orally over time. -
A Phase II 26-week double-blind placebo-controlled study to assess the safety tolerability pharmacokinetics and efficacy of ONO-2020 in patients with mild to moderate Alzheimer s Disease
This study will evaluate the safety and effectiveness of the drug ONO-2020 for mild to moderate Alzheimer's disease. The study will specifically investigate how ... -
A Phase II Study of DRP-104 a glutamine antagonist in patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer and Gastroesophageal Cancer
This is a Phase 2 study testing a new medicine called DRP-104 (a glutamine antagonist) in patients with non-small cell lung cancer (NSCLC). These patients ...
-
IMVT-1402-2801 - A Phase 2b Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Study to Assess the Efficacy Safety and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren s Disease with Moderate to Severe Systemic Disease Activity
The purpose of this study is to see if IMVT-1402 is safe and helps people with Sjogren’s Disease (SjD) with moderate-to-severe disease activity. -
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
This is a Phase 2 study testing whether a combination of TAS-102 and fruquintinib (a selective oral kinase inhibitor) is more effective and safer than ...